Core Viewpoint - Huakang Clean experienced a stock price decline of 2.01% on October 22, with a current price of 34.04 CNY per share and a total market capitalization of 3.668 billion CNY [1] Group 1: Stock Performance - Year-to-date, Huakang Clean's stock price has increased by 68.84%, with a recent decline of 1.36% over the last five trading days [1] - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 31 [1] Group 2: Financial Performance - For the first half of 2025, Huakang Clean reported a revenue of 833 million CNY, representing a year-on-year growth of 50.73%, and a net profit of 18.683 million CNY, up 273.48% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 40.0214 million CNY, with 29.4614 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of October 10, 2023, Huakang Clean had 10,500 shareholders, a decrease of 1.58% from the previous period, with an average of 6,898 circulating shares per shareholder, an increase of 1.60% [2] - Notable new institutional shareholders include Anxin Medical Health Stock A, holding 652,800 shares, and Nuoan Multi-Strategy Mixed A, holding 429,900 shares [3] Group 4: Business Overview - Huakang Clean, established on November 12, 2008, and listed on January 28, 2022, specializes in the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1] - The company's revenue composition includes 85.24% from purification system integration, 8.53% from medical consumables, 3.74% from medical equipment sales, 1.88% from operation services, and 0.61% from other sources [1]

转债代码：123251 转债简称：华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025-117 武汉华康世纪洁净科技股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第二十二次会议、第二届监事会第二十一次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，分别审议通过了《关于公司为子公司向 银行申请综合授信提供担保的议案》，同意公司为合并报表范围内的子公司湖北 菲戈特医疗科技有限公司、武汉光谷大健康医疗服务有限责任公司（以下简称"光 谷大健康"）申请银行综合授信额度提供不超过 70,000 万元（含本数）的连带 责任担保，担保额度在有效期内可以滚动使用，公司可在被担保对象间灵活调配 使用。上述授信额度及担保额度有效期自公司股东大会审议通过之日起十二个月 内。具体内容详见公司于 2025 年 4 月 25 日在中国证监会指定信息披露网站巨潮 资讯网披露的《关于公 ...

Core Viewpoint - The stock of Huakang Clean has experienced fluctuations, with a year-to-date increase of 65.57% but a recent decline in the last five trading days by 2.40% [1] Financial Performance - For the first half of 2025, Huakang Clean achieved a revenue of 835 million yuan, representing a year-on-year growth of 50.73%, and a net profit attributable to shareholders of 18.68 million yuan, up 273.48% year-on-year [2] - The company has distributed a total of 40.02 million yuan in dividends since its A-share listing, with 29.46 million yuan distributed over the past three years [3] Stock Market Activity - As of October 20, Huakang Clean's stock price was 33.38 yuan per share, with a market capitalization of 3.597 billion yuan [1] - The stock has seen significant trading activity, with a turnover of 92.99 million yuan and a turnover rate of 3.77% on the same day [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 31 [1] Shareholder Information - As of October 10, the number of shareholders for Huakang Clean was 10,500, a decrease of 1.58% from the previous period, while the average number of circulating shares per person increased by 1.60% to 6,898 shares [2] - Notable new institutional shareholders include Anxin Medical Health Stock A and Nuoan Multi-Strategy Mixed A, holding 652,800 shares and 429,900 shares respectively [3] Business Overview - Huakang Clean, established on November 12, 2008, and listed on January 28, 2022, specializes in the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1] - The revenue composition of the company includes 85.24% from purification system integration, 8.53% from medical consumables, 3.74% from medical equipment sales, 1.88% from operation services, and 0.61% from other sources [1]

Core Viewpoint - Huakang Clean Technology is a professional provider of integrated cleanroom system solutions, focusing on clean technology and offering comprehensive technical services throughout the project lifecycle [2] Company Overview - The company provides a full range of services related to cleanroom construction, including project consulting, planning, detailed design, project management, engineering construction, system debugging, secondary supporting projects, and after-sales maintenance [2]

（编辑 王雪儿） 证券日报网讯 华康洁净10月16日在互动平台回答投资者提问时表示，公司在洁净技术领域已具备成熟 的技术团队、经过项目验证的高效交付体系以及稳定的供应链保障，能够确保项目顺利落地并达到相应 的洁净标准。关于技术水平，公司当前的洁净技术已满足洁净项目要求，并已在多个项目中成功应用。 同时，公司已制定清晰的技术升级路线，致力于不断提升在行业中的技术地位。 ...

Core Insights - Huakang Clean (301235) reported that as of October 10, 2025, the total number of shareholders is 10,544 [1] Company Summary - The company is actively engaging with investors through interactive platforms [1] - The shareholder count indicates a growing interest in the company, which may reflect its market performance and investor confidence [1]

武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第二届董事会第十八次会议、第二届监事会第十七次会议，审议通过 了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司在保证日 常经营运作资金需求、有效控制投资风险的情况下，使用不超过 5,000 万元人民 币的闲置募集资金暂时补充流动资金，用于与主营业务相关的生产经营，使用期 限自董事会审议通过之日起不超过 12 个月，公司将随时根据募集资金投资项目 的进展及需求情况及时将暂时补流的募集资金归还至募集资金专用账户。具体内 容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2024-088）。 在使用闲置募集资金暂时补充流动资金期间，公司严格遵守《上市公司募集 资金监管规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》及公司《募集资金管理 制度》等相关规定，用于暂时补充流动资金的闲置募集资金仅用于与主营业务相 关的生产经营使用，资金使用安排合理，不存在改变或变相改变 ...

Core Insights - Huakang Clean's stock price increased by 5.3% to 34.96 CNY per share, with a trading volume of 95.89 million CNY and a turnover rate of 3.91%, resulting in a total market capitalization of 3.768 billion CNY [1] Company Overview - Wuhan Huakang Century Clean Technology Co., Ltd. is located in the East Lake New Technology Development Zone, Wuhan, Hubei Province, and was established on November 12, 2008, with its listing date on January 28, 2022 [1] - The company's main business involves the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1] - Revenue composition: Purification system integration accounts for 85.24%, medical consumables sales 8.53%, medical equipment sales 3.74%, operation and maintenance services 1.88%, and other supplementary services 0.61% [1] Shareholder Insights - Anxin Fund has a presence among Huakang Clean's top ten circulating shareholders, with Anxin Medical Health Stock A (010709) newly entering the top ten in the second quarter, holding 652,800 shares, which is 1.28% of the circulating shares [2] - The estimated floating profit for Anxin Medical Health Stock A today is approximately 1.1489 million CNY [2] - Anxin Medical Health Stock A was established on January 12, 2021, with a latest scale of 442 million CNY, achieving a year-to-date return of 64.37%, ranking 201 out of 4220 in its category [2] Fund Management - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who has been in the position for 4 years and 276 days, managing a total fund size of 946 million CNY [3] - During his tenure, the best fund return was 56.95%, while the worst return was 53.28% [3]

Core Viewpoint - Huakang Clean (301235) announced that as of the date of the announcement, the company has no overdue guarantees, no litigation-related guarantees, and has not incurred losses due to guarantees, nor has it provided guarantees for its controlling shareholders, actual controllers, or their affiliates [1] Summary by Relevant Sections - Company Status - The company confirmed the absence of overdue guarantees [1] - There are no ongoing litigations related to guarantees [1] - The company has not been ordered to bear losses due to guarantee failures [1] - No guarantees have been provided for controlling shareholders or their affiliates [1]

武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第二十二次会议、第二届监事会第二十一次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，分别审议通过了《关于公司为子公司向 银行申请综合授信提供担保的议案》，同意公司为合并报表范围内的子公司湖北 菲戈特医疗科技有限公司、武汉光谷大健康医疗服务有限责任公司（以下简称"光 谷大健康"）申请银行综合授信额度提供不超过 70,000 万元（含本数）的连带 责任担保，担保额度在有效期内可以滚动使用，公司可在被担保对象间灵活调配 使用。上述授信额度及担保额度有效期自公司股东大会审议通过之日起十二个月 内。具体内容详见公司于 2025 年 4 月 25 日在中国证监会指定信息披露网站巨潮 资讯网披露的《关于公司为子公司向银行申请综合授信提供担保的公告》（公告 编号：2025-039）。 二、本次担保进展情况 证券代码：301235 证券简称：华康洁净 公告编号：2025-115 转债代码：123251 转债简称：华医转债 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准 ...